Biotech Startups

Invive applies epigenetics to life insurance, using a saliva test to measure lifestyle factors such as smoking and alcohol consumption as an alternative to the blood-test standard. It targets insurers, reinsurers, and distributors in the insurance industry.

1 investor

InVivo Bionics develops implantable sensor systems for medical monitoring, initially focused on bladder health in urology. The company combines expertise in sensor electronics, software, and medical devices to create minimally invasive monitoring solutions with potential applications across multiple organ systems.

1 investor

Invizius develops therapeutics targeting the complement system to treat kidney disease and other disorders driven by uncontrolled immune activation. The company was founded based on research from the University of Edinburgh and operates from Glasgow Biocity.

1 investor

Invoke develops personalized cancer treatments using computational biology to predict neoantigens with greater accuracy by modeling individual tumor evolution and immune dynamics. The company serves cancer patients through neoantigen prediction models designed for treatment personalization.

1 investor

Ionara Bio is developing a therapeutic intervention that targets the critical 7-day window after a heart attack, modulating cardiac repair and inflammation to reduce adverse ventricular remodeling and prevent progression to heart failure. The company's approach involves TRPV2 inhibition to limit pathological myocardial fibrosis and scarring following myocardial infarction.

1 investor

IONETIX manufactures radiopharmaceuticals and operates a network of compact superconducting cyclotrons for PET imaging and cancer therapy production. The company produces N-13 Ammonia tracers for cardiac imaging and targeted alpha therapy radiopharmaceuticals for oncology applications.

1 investor

Ionis Pharmaceuticals is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted medicines using its antisense chemistry platform for people with serious diseases. Its pipeline spans neurologic conditions, cardiometabolic disorders, and other high-need areas.

1 investor

iota Biosciences develops bioelectronic diagnostic and therapeutic devices using ultrasound technology to improve patient care. The company partners with Astellas Pharma to bring innovative medical technologies to market.

1 investor

IP-GeoScape provides a visual mapping of the molecular intellectual property space for a given chemical area, showing relationships between molecules and highlighting occupied and unoccupied IP spaces. It serves pharmaceutical and chemistry R&D teams — including medicinal chemists, patent specialists, and licensing professionals — to support molecule discovery, patent prosecution, and freedom-to-operate analysis.

1 investor

Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs) for various therapeutic segments, serving healthcare markets across 120 countries. The company operates fully-automated manufacturing facilities approved by major regulatory authorities including UK-MHRA, EDQM-Europe, and WHO-Geneva.

1 investor

Implant Preservation Devices develops orthopedic implant devices for medical and surgical applications. The company focuses on launching and commercializing orthopedic implant solutions across European and emerging markets.

1 investor

iPeace develops automated manufacturing systems for iPS cell production using biotech and engineering techniques to reduce production costs and enable mass manufacturing of clinical-grade stem cells. The company serves the regenerative medicine and pharmaceutical research sectors with mass-produced, personalized cell lines.

1 investor

IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Its technology originated from research at Weill Cornell Medicine and the Hospital for Special Surgery, and it is advancing these preclinical programs toward clinical applications.

1 investor

iQ Sense develops biosensing tools that combine nanotechnology and artificial intelligence to detect signs of animal disease earlier, serving the veterinary and animal-health industry. The company runs programs in the UK, Australia, and USA and partners with universities, research bodies, and animal-health companies.

1 investor

IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used either in combination with ursodeoxycholic acid or as a standalone treatment for patients unable to tolerate standard therapy.

1 investor

iRen develops medical technology for dialysis patients, enabling them to continue daily activities while undergoing treatment. The company aims to reduce the burden of dialysis on quality of life for people with kidney disease.

1 investor

IROA Technologies develops scientific measurement infrastructure for metabolomics, combining stable isotope chemistry, reference standards, authentic metabolite libraries, software, and data analytics to improve the accuracy and reproducibility of biological measurements. It serves researchers, clinicians, and innovators in the life sciences and biological research field.

1 investor

Ironic Biotech develops an iron supplement designed for better absorption and gastrointestinal tolerance, aimed at women affected by iron deficiency. The company operates in the biotech and women's health space.

1 investor

iRubis develops Monipa, a Process Analytical Technology (PAT) tool using mid-infrared (MIR) spectroscopy to monitor bioprocess parameters inline or online in real time. It targets biopharmaceutical downstream process development and scale-up, measuring proteins, excipients, mRNA, and pDNA.

1 investor

The Institute for Systems Biology (ISB) is a research organization focused on systems biology science and education, including curriculum development, educator engagement, and student research programs.

1 investor

Isolation Bio develops technology and services for accelerated microbial research and discovery. The company offers the Prospector platform for high-throughput microbial screening and cultivation, alongside custom microbial isolation and cultivation services for researchers.

1 investor

Isomab develops first-in-class antibody therapies targeting specific VEGF-A isoforms to restore blood vessel growth and improve blood flow in cardiovascular diseases. The company was spun out of the University of Nottingham in 2022 and builds on over 20 years of vascular biology research.

1 investor

IsoPlexis offers the Cell Analysis Suite (CAS), software for its Beacon optofluidic platform that lets researchers design, automate, and analyze functional live single-cell workflows. It serves life-science researchers working in areas such as antibody discovery, cell line development, T cell profiling, and adoptive cell therapy.

1 investor

Isospec Analytics provides glycome and metabolome analysis for biomarker discovery, combining liquid chromatography-mass spectrometry with proprietary CIRIS technology and AI to identify molecular signatures beyond current library limitations.

1 investor